Inhibrx Biosciences, Inc.: Q2 FY2026 earnings call
What management said about Q2 FY2026, from the documents filed with the SEC on 13 August 2026: press release. Guidance figures: 1 raised, 3 new. The quarter’s numbers.
Key takeaways
- Quarterly net loss widened: Net loss was $36.7 million, or $2.34 per share basic and diluted, against $28.7 million, or $1.85 per share, in the second quarter of 2025. Source
- R&D rose on ozekibart costs: R&D expense was $23.9 million versus $22.3 million, reflecting clinical trial and contract manufacturing costs tied to the ozekibart BLA. Personnel and clinical consulting costs fell. Source
- G&A rose on launch preparation: G&A expense was $8.3 million versus $6.4 million, from pre-commercialization spending on market access, launch and communication materials for ozekibart in chondrosarcoma. Source
- BLA accepted for filing: The FDA accepted the ozekibart BLA for conventional chondrosarcoma in June 2026. The BLA had been submitted in April 2026. Source
- PFS readout moved earlier: PFS data from the randomized Phase 2 HNSCC trial are now planned for the third quarter of 2026, previously the fourth quarter of 2026. Source
- Cash at August 6 higher: Cash and cash equivalents were $219.5 million on August 6, 2026, after $100.0 million of Oxford proceeds received on July 15, 2026. Source
- Stockholders' deficit deepened: Stockholders’ equity was a deficit of $53.0 million at June 30, 2026, compared with equity of $8.0 million at December 31, 2025 and a $21.0 million deficit at March 31, 2026. Source
- Amendment adds $325 million: The July 2026 Second Amendment with Oxford provides for an additional $325.0 million in gross proceeds. Source
“The Company did not recognize any revenue during the second quarter of 2026.”
Inhibrx Biosciences, Inc., press release
Guidance
| Area | Period | Figure | Against last quarter |
|---|---|---|---|
| INBRX-106 Phase 2 HNSCC PFS data Source | third quarter of 2026 | third quarter of 2026 | Raised from fourth quarter of 2026 |
| Ozekibart FDA meeting on colorectal cancer Source | fourth quarter of 2026 | fourth quarter of 2026 | |
| Ozekibart colorectal cohort interim results Source | first quarter of 2027 | first quarter of 2027 | New |
| Ozekibart BLA PDUFA goal date Source | April 14, 2027 | April 14, 2027 | New |
| Oxford loan additional funding Source | future funding increments | up to $225.0 million, in increments of $50.0 million or more | New |
What changed from last quarter
- Guidance raised: Timing for INBRX-106 HNSCC PFS data moved earlier, from the fourth quarter of 2026 to the third quarter of 2026. Source
- New guidance: Interim results from the new colorectal cancer cohorts were given a timing of the first quarter of 2027. Source
- New: The FDA accepted for filing the ozekibart BLA in conventional chondrosarcoma in June 2026, after the BLA was submitted in April 2026. Source
- New: Two additional Phase 1 colorectal cancer cohorts of ozekibart were initiated in the second quarter of 2026. Source
- New: In July 2026 the Company entered into a second amendment to its Oxford loan agreement, providing additional gross proceeds. Source
Results and net loss
- No revenue this quarter: No revenue was recognized in the second quarter of 2026, compared with $1.3 million a year earlier from completing the Scithera license transfer. Source
- Quarterly net loss widened: Net loss was $36.7 million, or $2.34 per share basic and diluted, against $28.7 million, or $1.85 per share, in the second quarter of 2025. Source
- Six-month net loss slightly lower: Net loss for the six months ended June 30, 2026 was $70.1 million, compared with $72.0 million in the same period of 2025. Source
- Other expense rose on interest: Other expense, net was $4.5 million versus $1.3 million, mainly from interest on a $175.0 million loan balance versus $100.0 million a year earlier, plus lower interest income. Source
Operating expense increases
- R&D rose on ozekibart costs: R&D expense was $23.9 million versus $22.3 million, reflecting clinical trial and contract manufacturing costs tied to the ozekibart BLA. Personnel and clinical consulting costs fell. Source
- G&A rose on launch preparation: G&A expense was $8.3 million versus $6.4 million, from pre-commercialization spending on market access, launch and communication materials for ozekibart in chondrosarcoma. Source
- Six-month R&D fell year over year: Six-month R&D expense was $49.1 million versus $59.1 million in the prior-year period. Source
“Net loss was $36.7 million during the second quarter of 2026, or $2.34 per share, basic and diluted”
Inhibrx Biosciences, Inc., press release
Ozekibart regulatory progress
- BLA accepted for filing: The FDA accepted the ozekibart BLA for conventional chondrosarcoma in June 2026. The BLA had been submitted in April 2026. Source
- PDUFA date set for April 2027: The FDA assigned a PDUFA goal date of April 14, 2027 for the ozekibart BLA in conventional chondrosarcoma. Source
- Two new colorectal cohorts started: Two additional Phase 1 colorectal cancer cohorts began in the second quarter, one second-line with Folfiri and Avastin and one third/fourth-line with Lonsurf and Avastin. Source
- FDA meeting on colorectal pathways: The Company plans an FDA meeting in the fourth quarter of 2026 on a first-line registrational CRC trial and an accelerated pathway in fourth-line CRC. Source
INBRX-106 readout timing
- May interim data released: Updated interim data from the randomized first-line Phase 2 portion of the HexAgon study were announced in May 2026. The trial compares INBRX-106 plus pembrolizumab with pembrolizumab alone.
- PFS readout moved earlier: PFS data from the randomized Phase 2 HNSCC trial are now planned for the third quarter of 2026, previously the fourth quarter of 2026. Source
- No new INBRX-106 data this quarter: The second-quarter release reports no new INBRX-106 trial results and describes the company as having two programs in ongoing clinical trials. Source
“The Company plans to meet with the FDA in the fourth quarter of 2026 to discuss plans to initiate a first-line registrational trial in CRC as well as the potential for an accelerated regulatory pathway for ozekibart in fourth-line CRC.”
Inhibrx Biosciences, Inc., press release
Cash and balance sheet
- Cash at June 30: Cash and cash equivalents were $133.3 million at June 30, 2026, up from $124.2 million at December 31, 2025. Source
- Cash at August 6 higher: Cash and cash equivalents were $219.5 million on August 6, 2026, after $100.0 million of Oxford proceeds received on July 15, 2026. Source
- Stockholders' deficit deepened: Stockholders’ equity was a deficit of $53.0 million at June 30, 2026, compared with equity of $8.0 million at December 31, 2025 and a $21.0 million deficit at March 31, 2026. Source
Oxford loan second amendment
- Amendment adds $325 million: The July 2026 Second Amendment with Oxford provides for an additional $325.0 million in gross proceeds. Source
- $100 million received July 15: The Company entered the Second Amendment on July 15, 2026 and received $100.0 million of gross proceeds. Source
- Further $225 million at discretion: Up to an additional $225.0 million may be funded at the Company's request, at Oxford's discretion, in increments of $50.0 million or more. Source
- Long-term debt rose: Long-term debt, net was $176.3 million at June 30, 2026, compared with $100.6 million at December 31, 2025. Source
Coming up, as management said on 13 August 2026
- INBRX-106 PFS data: PFS data from the randomized Phase 2 HNSCC trial with pembrolizumab are planned for the third quarter of 2026. Source
- Colorectal cohort interim results: Interim results from the two new Phase 1 colorectal cancer cohorts are expected in the first quarter of 2027. Source
- FDA meeting in fourth quarter: A meeting with the FDA is planned for the fourth quarter of 2026 on a first-line CRC registrational trial and accelerated pathway options. Source
- Ozekibart PDUFA goal date: The FDA review of the ozekibart BLA has a PDUFA goal date of April 14, 2027. Source
- Possible further Oxford funding: Additional Oxford funding of up to $225.0 million may be drawn in increments of $50.0 million or more, at Oxford's discretion. Source
Figures management reported
| Figure | Reported |
|---|---|
| R&D expense, second quarter of 2026 Source | $23.9 million |
| Ozekibart BLA status Source | Accepted for filing; PDUFA goal date April 14, 2027 |
| INBRX-106 PFS data timing Source | Third quarter of 2026 |
Earlier plans management reported on
- Not stated: The earlier plan for PFS data in the fourth quarter of 2026 was moved to the third quarter of 2026 in the second-quarter release.
- Not stated: The earlier plan for the FDA meeting in the second half of 2026 was narrowed to the fourth quarter of 2026.
Other quarters
Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.